Xtant Medical (NYSEAMERICAN:XTNT – Get Free Report) issued its quarterly earnings results on Monday. The medical device company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01), FiscalAI reports. Xtant Medical had a negative net margin of 10.17% and a negative return on equity of 23.45%. The business had revenue of $24.29 million for the quarter, compared to the consensus estimate of $25.48 million.
Xtant Medical Price Performance
Shares of Xtant Medical stock opened at $0.27 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.16 and a quick ratio of 1.05. The business’s 50 day simple moving average is $0.32 and its two-hundred day simple moving average is $0.44. The stock has a market capitalization of $38.12 million, a P/E ratio of -3.40 and a beta of -0.19. Xtant Medical has a one year low of $0.26 and a one year high of $0.84.
Analyst Upgrades and Downgrades
Separately, Loop Capital set a $1.00 price target on shares of Xtant Medical in a research note on Wednesday, September 2nd. Two analysts have rated the stock with a Buy rating. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $1.00.
Check Out Our Latest Report on Xtant Medical
Xtant Medical Company Profile
Xtant Medical Group, Inc. develops and markets medical products used in spine surgery. Its portfolio includes spinal implant systems and biologic products intended to support bone growth and spinal fusion. The company serves surgeons and healthcare providers, primarily in the United States, and also reaches select international markets through distribution relationships. Its products are used in procedures to treat spinal conditions and support stabilization or fusion. Xtant Medical’s business brings together spinal-device and biologics operations, including products developed through acquisitions.
See Also
- Five stocks we like better than Xtant Medical
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Receive News & Ratings for Xtant Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical and related companies with MarketBeat.com's FREE daily email newsletter.
